Buch, Englisch, 468 Seiten, Format (B × H): 178 mm x 254 mm
Reihe: Methods in Molecular Biology
Methods and Protocols
Buch, Englisch, 468 Seiten, Format (B × H): 178 mm x 254 mm
Reihe: Methods in Molecular Biology
ISBN: 978-1-0716-5718-8
Verlag: Springer Us
This detailed volume aims to serve researchers working in antibody-drug conjugate (ADC) development by guiding them through the entire process, from payload selection to QA/QC design for regulatory approval, while also providing a deeper understanding of the various stages of ADC evolution. While the rapid pace of technological advancements continues to reshape the ADC landscape, this book covers the foundational principles, key milestones, and the latest cutting-edge methodologies, presented by experts in the field. Written for the highly successful series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, and tips for troubleshooting and avoiding known pitfalls.
Authoritative and practical, is a valuable resource for designing and accelerating ADC development programs, inspiring and empowering scientists to further innovate in this field, ultimately contributing to the advancement of more effective and safer therapies.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Naturwissenschaften Biowissenschaften Biowissenschaften
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Interdisziplinäres Wissenschaften Wissenschaften: Forschung und Information Forschungsmethodik, Wissenschaftliche Ausstattung
Weitere Infos & Material
The Architecture of Antibody-Drug Conjugates: Key Design Parameters and Methodological Approaches.- ADC Payloads Past, Present, and Future.- An Integrated Introduction to Payload and Linker Design in ADC Development.- ADC Synthesis by Conjugation to Lysine Residues.- Cysteine Conjugated Antibody-Drug Conjugate (ADC) Production and Characterization.- Generating DAR 2 Antibody-Drug Conjugates Using Bis-Divinyl Pyrimidine Reagents.- Dual-Drug ADC Synthesis Using a Combination of Non-Natural Amino Acid and Cysteine-Based Conjugations.- Tag-Free Lipoic Acid Ligase A (LplA)-Mediated Modification Toward Antibody-Drug Conjugate Production.- Synthesis of Site-Specific Antibody-Drug Conjugates via Endoglycosidase-Catalyzed Fc Glycan Remodeling.- Preparation of Antibody-Oligonucleotide Conjugates.- Degrader Antibody Conjugates: Design Considerations Toward DAC Synthesis.- Radiolabeling of Monoclonal Antibodies with Zirconium-89 for Immuno-PET Imaging.- Preparation of 124I-Labeled Antibodies via Direct Electrophilic Substitution.- Preparing Site-Specific Antibody-Drug Conjugates (ADC) Through Noncanonical Amino Acid Mutagenesis.- Characterization of Antibody-Drug Conjugates Using Hydrophobic Interaction Chromatography Coupled with Mass Spectrometry.- In Situ RP-HPLC Analysis of Intact Antibody-Drug Conjugates for Reaction Monitoring and DAR Trend Estimation.- Antibody-Drug Conjugate (ADC) Characterization by Size Exclusion Chromatography Coupled with Mass Spectrometry.- ADC Characterization: Serum Stability Assessment Using LC-MS.- Light Mapping–Guided Photostability Assessment for Light-Sensitive Antibody-Drug Conjugates.- In Vitro Dose-Response and Cytotoxicity Assessment of ADCs.- In Vitro Evaluation of the Bystander Effect of Antibody-Drug Conjugates.- Bottom-Up LC-MS/MS Approach for Quantification of Total Antibody in Biological Matrices Following ADC Administration.- A Perspective on Manufacturability, Containment, and Facility Strategy for the Future of Antibody-Drug Conjugate Development.
